

Markers of Favorable Response to Complement Inhibitors Therapy

NCT06455709

Status RECRUITING
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (5)

- Age ≥18 years;
- Diagnosis of generalized anti-AChR positive Myasthenia Gravis;
- Need for therapy with complement inhibitor drugs according to the therapeutic indications approved by AIFA (16);
- Ability to perform follow-up at the reference center;
- Signed informed consent to the study.

Exclusion (6)

- Age <18 years;
- Poor compliance with drug therapy;
- Concomitant autoimmune diseases;
- Insufficient availability of clinical information;
- Ongoing neoplasia or infection at the time of biological sample collection;
- ... and 1 more (see full listing online)

Locations (1 total)

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy